Cardiovascular Disease Doctors in East Greenwich, RI Accepting Medicare

5 Cardiovascular Disease doctors found. Showing 1 - 5

Mr. Brian G Abbott, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1377 S County Trl, East Greenwich, RI 02818 Phone: 401-886-7590    Fax: 401-886-7571

Dr. David J Broza, MD Internal Medicine - Cardiovascular Disease Medicare: May Accept Medicare Assignments Practice Location: 3461 S County Trl, East Greenwich, RI 02818 Phone: 401-471-6440    Fax: 401-889-5082

Joseph A. Wyllie, DO Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1377 South County Trail, East Greenwich, RI 02818 Phone: 401-226-7590    Fax: 401-886-7571

Lincoln Tirpaeck, DO Internal Medicine - Cardiovascular Disease Medicare: May Accept Medicare Assignments Practice Location: 3461 S County Trl, East Greenwich, RI 02818 Phone: 401-471-6440    Fax: 401-889-5082

Dr. Karen E Aspry, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1377 South County Trail, East Greenwich, RI 02818 Phone: 401-886-7590    Fax: 401-886-7571

News Archive

Clinical study uses genetic testing to match AML patients with new therapies

A clinical trial using genetic testing to match acute myeloid leukemia (AML) patients with new therapies is now open at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

Self-treatment lowers overall health care costs for chronic obstructive pulmonary disorder sufferers

Individuals suffering from chronic obstructive pulmonary disorder (COPD) can experience significant savings in healthcare costs by employing a self-treatment program with the judicious use of medications, according to the results of a new study. The self-treatment program achieves these savings by reducing the duration of flare-ups.

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.

Astute Medical completes $26.5 million series B financing

Astute Medical, Inc., a developer of novel, biomarker-based medical diagnostics, today announced completion of a $26.5 million series B financing co-led by Domain Associates and Delphi Ventures. Astute will use the funding to advance research and development aimed at the identification and validation of protein biomarkers with the goal of commercializing high potential diagnostic products.

Read more Medical News

› Verified 9 days ago